Suppression of AKT phosphorylation restores rapamycin-based synthetic lethality in SMAD4-defective pancreatic cancer cells

Molecular Cancer Research

Volumn 11, Issue 5, 2013, Pages 474-481

  Le Gendre, Onica ^a   Sookdeo, Ayisha ^a   Duliepre, Stephie Anne ^a   Utter, Matthew ^a   Frias, Maria ^a   Foster, David A ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; RAPAMYCIN; SERINE; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; LETHALITY; PANCREAS CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL LINE, TUMOR; EUKARYOTIC INITIATION FACTOR-4E; GENE KNOCKDOWN TECHNIQUES; HUMANS; MULTIPROTEIN COMPLEXES; PANCREATIC NEOPLASMS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; SMAD4 PROTEIN; TOR SERINE-THREONINE KINASES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84877884032     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0679     Document Type: Article

References (38)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70.
2. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93.
3. Polak P, Hall MN. mTOR and the control of whole body metabolism. Curr Opin Cell Biol 2009;21:209-18.
4. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12:21-35.
5. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
6. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012;21:297-308.
7. Blagosklonny MV. Molecular damage in cancer: an argument for mTOR-driven aging. Aging 2011;3:1130-41.
8. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 2005;11:353-61.
9. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-74.
10. Sawyers CL. Will mTOR inhibitors make it as cancer drugs? Cancer Cell 2003;4:343-8.
11. Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 2012;30: 2919-28.
12. Gadir N, Jackson DN, Lee E, Foster DA. Defective TGF-β signaling sensitizes human cancer cells to rapamycin. Oncogene 2008;27: 1055-62.
13. Yellen P, Saqcena M, Salloum D, Feng J, Preda A, Xu L, et al. Highdose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex1 and suppressing phosphorylation of 4E-BP1. Cell Cycle 2011;10:3948-56.
14. Jaffee EM, Hruban RH, Canto M, Kern SE. Focus on pancreas cancer. Cancer Cell 2002;2:25-8.
15. Levy L, Hill CS. Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 2006;17:41-58.
16. Foster DA, Gadir N. Can defective TGF-β signaling be an Achilles heel in human cancer? Chin J Cancer 2008;27:882-4.
17. Reinhardt HC, Jiang H, Hemann MT, Yaffe MB. Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle 2009;8: 3112-9.
18. Loewith R, Hall MN. Target of rapamycin (TOR) in nutrient signaling and growth control. Genetics 2011;189:1177-201.
19. Chen Y, Rodrik V, Foster DA. Alternative phospholipase D/mTOR survival signal in human breast cancer cells. Oncogene 2005;24: 672-9.
20. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol 2009;29:1411-20.
21. Azar R, Alard A, Susini C, Bousquet C, Pyronnet S. 4E-BP1 is a target of Smad4 essential for TGFβ-mediated inhibition of cell proliferation. EMBO J 2009;28:3514-22.
22. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376: 37-43.
23. Tewari M, Quan LT, Orourke K, Desnoyers S, Zeng Z, Beidler DR, et al. Yama/Cpp32-b, amammalian homolog of Ced-3, is a Crma-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995;81:801-9.
24. Song K, Wang H, Krebs TL, Danielpour D. Novel roles of Akt and mTOR in suppressing TGF-β/ALK5-mediated Smad3 activation. EMBO J 2006;25:58-69.
25. Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 2004;167:399-403.
26. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8.
27. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-8.
28. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005;9:59-71.
29. Osman B, Doller A, Akool el S, Holdener M, Hintermann E, Pfeilschifter J, et al. Rapamycin induces the TGFbeta1/Smad signaling cascade in renal mesangial cells upstream of mTOR. Cell Signal 2009;21: 1806-17.
30. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009;284: 8023-32.
31. Zimmer SG, DeBenedetti A, Graff JR. Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Research 2000;20:1343-51.
32. Soni A, Akcakanat A, Singh G, Luyimbazi D, Zheng Y, Kim D, et al. eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Molecular Cancer Therapeutics 2008;7: 1782-8.
33. Barcellos-Hoff MH, Akhurst RJ. Transforming growth factor-b in breast cancer: too much, too late. Breast Cancer Res 2009;11:202.
34. Blagosklonny MV. Molecular damage in cancer: an argument for mTOR-driven aging. Aging (Albany NY) 3:1130-41.
35. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-b superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002;62:65-74.
36. Ryer EJ, Hom RP, Sakakibara K, Nakayama KI, Nakayama K, Faries PL, et al. PKCd is necessary for Smad3 expression and transforming growth factor b-induced fibronectin synthesis in vascular smooth muscle cells. Arterioscler, thrombosis, and vascular biology 2006:26; 780-6.
37. Susarla BT, Robinson MB. Rottlerin, an inhibitor of protein kinase Cd (PKCd), inhibits astrocytic glutamate transport activity and reduces GLAST immunoreactivity by a mechanism that appears to be PKC dindependent. J neurochem 2003;86:635-45.
38. Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 2010;328:1172-6.